MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: IMARC Group
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

IMARC Group Publishes New Report Analyzing the Potential of Therapeutic Monoclonal Antibodies in India - Research firm IMARC Group expects this market to grow at a CAGR of around 26% during 2013-2016, according to its latest report entitled “Indian Monoclonal Antibodies Market Report & Forecast: 2012-2016” - IMARCgroup.com
IMARC Group Publishes New Report Analyzing the Potential of Therapeutic Monoclonal Antibodies in India

 

NewswireToday - /newswire/ - New Delhi, Delhi, India, 2013/04/11 - Research firm IMARC Group expects this market to grow at a CAGR of around 26% during 2013-2016, according to its latest report entitled “Indian Monoclonal Antibodies Market Report & Forecast: 2012-2016” - IMARCgroup.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

A huge patient pool, increasing prevalence of health insurance, strong biosimilar manufacturing capabilities and a largely unpenetrated market are expected to be the catalysts in driving the market for monoclonal antibodies in India. Research firm IMARC Group expects this market to grow at a CAGR of around 26% during 2013-2016, according to its latest report entitled “Indian Monoclonal Antibodies Market Report & Forecast: 2012-2016”.

According to an analyst at IMARC Group,“India’s poor historical track record in Intellectual property protection has resulted in many Indian companies acquiring strong reverse engineering skills. The Indian generic industry provides generic drugs not only to India but to the entire world. India currently has more FDA approved manufacturing facilities than any other country outside the US. Globally there are only 2 approved biosimilar monoclonal antibodies with Reditux (Rituximab) (developed and manufactured by Dr. Ready’s, an Indian generic manufacturer) being one of them. As a result, India and its biosimilar manufacturers can be regarded as the front runners in the global biosimilar antibody market race”.

Key Aspects Analyzed in this Report:

- Understanding the strengths, weaknesses, opportunities and challenges in the Indian monoclonal antibodies market

- Understanding the technological considerations and regulatory factors in the Indian monoclonal antibodies market
• Evaluation and identification of monoclonal antibodies based on the sources from which they are derived and on the targets against which they act
• Understanding the key regulations for registering, manufacturing and importing monoclonal antibodies in India

- Evaluating the patent details of all globally marketed monoclonal antibodies in India, US and Europe
• Identifying the patentee name and patent numbers of all in-market monoclonal antibodies in India, US and Europe
• Identifying the monoclonal antibodies that are patent protected in India, US and Europe and those that are not
• Estimating the patent expiries of various monoclonal antibodies in India, US and Europe

- Comprehensive situation analysis of the Indian monoclonal antibodies market
• Analyzing current and future sales of monoclonal antibodies in India
• Identifying all globally launched monoclonal antibodies and understanding their performance and launch status in India
• Analyzing the global and Indian monoclonal antibodies market by Indication
• Evaluation of the top selling monoclonal antibodies
• Key biosimilar antibody development programmes in India and abroad.

Table of Contents

1 Market Definitions & Methodology
2 Executive Summary
3 Therapeutic Antibodies Market in India
3.1 Industry Analysis
3.1.1 Strengths
3.1.2 Weaknesses
3.1.3 Opportunities
3.1.4 Threats
3.2 Technological & Regulatory Assessment
3.2.1 Technological Assessment
3.2.2 Regulatory Assessment
3.3 Patent Details of Various Monoclonal Antibodies: US, Europe & India
3.4 Market Analysis
3.4.1 Current & Future Sales Trends
3.4.2 Sales Breakup by Molecule
3.4.3 Sales by Indication
3.5 Evaluation of Top Monoclonal Antibodies
3.5.1.1 Avastin
3.5.1.2 Herceptin
3.5.1.3 Rituxan/Mabthera
3.5.1.4 Remicade
3.5.1.5 Humira
3.6 Biosimilar Case Studies
5.6.1 Reditux
5.6.2 Grafeel
3.7 Key Indian & Foreign Biosimilar Antibody Development Programmes.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: IMARC Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


IMARC Group Publishes New Report Analyzing the Potential of Therapeutic Monoclonal Antibodies in India

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Krishna Sharma - IMARCgroup.com 
+91 12 04155099 press[.]imarcgroup.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IMARC Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From IMARC Group / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Technological Advancements in Manufacturing Boost the Cell and Gene Therapy Market Says Frost & Sullivan
Huami Corp and Royal DSM Announce Collaboration on Wearable Technologies and Health Tracking for Personalized Nutrition
DSM Expands Animal Nutrition & Health Operations in China with Opening of Seventh Premix Plant
Biosurfactants and Natural Preservatives Drive Innovation for Functional Ingredients in Personal Care Market Finds Frost & Sullivan
Ypsomed Collaborates with SCHOTT and Lonza to Develop A Comprehensive Solution for Combination Products Based on Patch Injectors
DSM Unveils Purpose-led Brand Strategy Marking Transition to End-to-end Partner in Nutrition and Health
Ipsen to Present 12 Abstracts At the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress
Imec Announces elPrep5 - the Newest Version of its Software Platform for DNA Analysis
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  Calmerry





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)